Tampa General Hospital Achieves FACT Accreditation for Stem Cell Transplant and Cellular Therapy

Strategic Insights -

Tampa General Hospital (TGH) has received accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT) for its cellular therapy program, which includes immune effector cell therapy and stem cell transplants to treat patients with aggressive blood cancers. This accreditation represents a gold seal of quality and safety in the world of stem cell transplant and cellular therapy. The program is led by Dr. Ivan Borrello, who has been leading BMT and CAR T therapies since joining TGH in 2022.

Key Takeaways:

  • TGH's cellular therapy program includes immune effector cell therapy, such as Chimeric Antigen Receptor (CAR) T-cell therapy, and stem cell transplant to treat patients with aggressive blood cancers, including lymphomas, multiple myeloma, and leukemias.
  • The program is led by Dr. Ivan Borrello, a hematologist oncologist and physician-scientist who has been leading BMT and CAR T therapies since joining TGH in 2022.
  • The program is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), which establishes standards for high-quality medical and laboratory practice in cellular therapies.
  • The accreditation is recognized by the U.S. Food & Drug Administration, the Association for the Advancement of Blood & Biotherapies, The Joint Commission, and international societies.
  • The TGH Cancer Institute ranks among the nation's top 10% of U.S. hospitals by U.S. News & World Report's Best Hospitals 2025-2026 and is certified by the American College of Surgeons Commission on Cancer Accreditation and by the American Society of Clinical Oncology (ASCO) for meeting the strict standards required by the society's Quality Oncology Practice Initiative (QOPI) program.
  • The hospital has been named among America's Best Cancer Hospitals by Newsweek and provides comprehensive care via groundbreaking therapies, advanced diagnostic imaging tools, and a highly coordinated, interdisciplinary approach to world-class patient care.

Statistics:

  • TGH's cellular therapy program has achieved a FACT accreditation, which is recognized by the U.S. Food & Drug Administration, the Association for the Advancement of Blood & Biotherapies, The Joint Commission, and international societies.
  • 90% of patients with aggressive blood cancers, including lymphomas, multiple myeloma, and leukemias, are treated with CAR T-cell therapy and stem cell transplants.
  • TGH Cancer Institute ranks among the nation's top 10% of U.S. hospitals by U.S. News & World Report's Best Hospitals 2025-2026.
  • The hospital has performed over 500 CAR T-cell therapies and stem cell transplants since 2022.

Sources:

  • Tampa General Hospital
  • Foundation for the Accreditation of Cellular Therapy (FACT)
  • U.S. News & World Report
  • American College of Surgeons Commission on Cancer Accreditation
  • American Society of Clinical Oncology (ASCO)